|
Oct 1
|
Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions
|
|
Sep 29
|
2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk
|
|
Jul 26
|
Intellia (NTLA) to Report Q2 Earnings: What's in the Cards?
|
|
Jul 24
|
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
|
|
Jul 23
|
7 Biotech Stocks to Keep on Your Clinical Radar
|
|
Jun 17
|
Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024
|
|
Jun 14
|
Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry
|
|
Jun 14
|
Intellia Therapeutics Names Brian Goff to its Board of Directors
|
|
Jun 9
|
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
|
|
Jun 2
|
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
|
|
May 25
|
ARK Invest's Cathie Wood Snags These 3 Bargains — Are They Right for Your Portfolio?
|
|
May 14
|
Intellia Therapeutics, Inc. (NTLA) Just Overtook the 50-Day Moving Average
|
|
May 12
|
Earnings Beat: Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
|
|
May 10
|
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2024 Earnings Call Transcript
|
|
May 10
|
Intellia Therapeutics Q1 2024 Earnings: Aligns with Analyst Projections Amidst Strategic Advances
|
|
May 10
|
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
|
|
May 10
|
Intellia's (NTLA) Q1 Earnings & Revenues Beat Estimates
|
|
May 10
|
Intellia Therapeutics First Quarter 2024 Earnings: Beats Expectations
|
|
May 10
|
Q1 2024 Intellia Therapeutics Inc Earnings Call
|
|
May 9
|
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates
|